We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Merck and Co Inc | NYSE:MRK | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.81 | 0.63% | 128.38 | 128.674 | 127.01 | 127.01 | 962,836 | 15:20:28 |
From May 2019 to May 2024
By Carlo Martuscelli
AstraZeneca PLC (AZN.LN) said Wednesday that cancer drug Lynparza met its primary objective in a clinical trial, making it the only drug in its class with positive phase 3 study results for prostate cancer.
The treatment, which is being developed in cooperation with Merck & Co. (MRK), was able to slow disease progression in patients with a specific prostate cancer type, AstraZeneca said.
The British pharmaceutical company said that it will present the full results from the PROfound trial at an upcoming medical conference.
Lynparza was administered to previously treated men with prostate cancer that was resistant to castration and with mutations in their BRCA1/2 or ATM genes.
With this result the drug is the only one of its class, known as PARP inhibitors, that has shown positive results in phase 3 trials across ovarian, breast, pancreatic and prostate cancer, Astra said.
Write to Carlo Martuscelli at carlo.martuscelli@dowjones.com
(END) Dow Jones Newswires
August 07, 2019 02:53 ET (06:53 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Merck Chart |
1 Month Merck Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
